According to Greg Brockman (@gdb), OpenAI's GPT-5 is being applied in immunology, signaling a significant advancement in the use of large language models for biomedical research and clinical diagnostics (source: Greg Brockman on Twitter). The new version of GPT-5 is reported to enhance data analysis, accelerate literature review, and support hypothesis generation in immunological studies. This development opens business opportunities for biotech companies to integrate AI-powered solutions in drug discovery, personalized medicine, and disease prediction, making AI an essential tool in the competitive life sciences sector.